Utah Medical ProductsUTMD
UTMD
About: Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
Employees: 167
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.06% more ownership
Funds ownership: 68.0% [Q4 2024] → 68.06% (+0.06%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 36
4% less funds holding
Funds holding: 112 [Q4 2024] → 108 (-4) [Q1 2025]
12% less capital invested
Capital invested by funds: $142M [Q4 2024] → $125M (-$16.6M) [Q1 2025]
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
Research analyst outlook
We haven’t received any recent analyst ratings for UTMD.
Financial journalist opinion
Neutral
Accesswire
1 month ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Positive
Seeking Alpha
1 month ago
Stock Picks From Seeking Alpha's April 2025 New Analysts
In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside.
Negative
Zacks Investment Research
1 month ago
Utah Medical Q1 Earnings Drop 16% on Sales Slump, Stock Up 1%
UTMD's Q1 2025 earnings fall 16% amid weak OEM sales, FX pressures and higher taxes, despite lower litigation costs and a strong cash position.
Neutral
Accesswire
1 month ago
Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2025
SALT LAKE CITY, UT / ACCESS Newswire / April 29, 2025 / In the first calendar quarter (1Q) of 2025, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results consistent with its previously announced projections for calendar year 2025. Summary of results.
Positive
Seeking Alpha
1 month ago
Utah Medical Products: Quietly Profitable--A Deep Value Gem Hiding In The Open
Utah Medical Products develops and manufactures medical devices focused on women's health, obstetrics, gynecology, and blood pressure monitoring. The company's stock price has declined due to a drop in sales from a key U.S. customer, weaker performance in international markets, and ongoing litigation. Despite recent challenges, the company has a consistent track record of profitability, a fortress balance sheet, and a disciplined capital allocator in the CEO.
Neutral
Accesswire
4 months ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Negative
Zacks Investment Research
4 months ago
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
Neutral
Accesswire
4 months ago
UTMD Reports Year 2024 and Fourth Quarter Financial Performance
SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.
Positive
Seeking Alpha
5 months ago
Utah Medical Products: Favorably Skewed Risk/Reward Profile
UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share.
Neutral
Accesswire
7 months ago
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S.
Charts implemented using Lightweight Charts™